Acquisition Target Pharmatek was acquired by Catalent in 2016, indicating integration into a larger CDMO network. This suggests potential opportunities to offer services that complement Catalent’s expanded bioavailability and formulation capabilities, especially for clients seeking specialized HP/C manufacturing and seamless outsourcing integration.

Midmarket Focus With 51-200 employees and annual revenue likely in the 50–100 million range, Pharmatek sits in a mid-market segment that often seeks scalable development and GMP manufacturing partnerships. Target expansion into additional high-potency and cytotoxic programs, early formulation development, and global packaging/logistics could attract mid-sized pharma and biotech clients.

Full Development Stack Pharmatek offers end-to-end services from discovery support to cGMP manufacturing, clinical packaging, labeling, worldwide distribution, stability testing, and HP/C compound handling. Sales opportunities exist in offering integrated, one-stop solutions for programs moving from discovery through clinical trials, reducing vendor management overhead for clients.

Global Distribution Potential Capabilities include worldwide distribution and stability testing, suggesting promotions to global biotech and pharma companies seeking robust international supply chain and regulatory-compliant packaging for multicountry clinical trials.

Strategic Partnerships The historical acquisition by Catalent signals a preference for strategic partnerships within a larger CDMO ecosystem. Positioning as a complementary partner for niche expertise in HP/C formulation and specialized manufacturing could win collaboration opportunities, co-development projects, and preferred vendor status on complex programs.